SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

More documents

Recommendations

Info

I N T R O D U C T I O N A N D P R O G R E S S R E P O R T I N T R O D U C T I O N A N D P R O G R E S S R E P O R T W. Jarrard Goodwin, M.D., F.A.C.S. Director, University of Miami Sylvester Comprehensive Cancer Center INTRODUCTION Since publishing our last Scientific Report in 2002, much has changed at the University of Miami Sylvester Comprehensive Cancer Center. We have recruited more than 25 new faculty members, most of whom are physician-scientists, reflecting our commitment to translational research. Our Institutional Review Board has approved and opened 160 therapeutic clinical trials. We have strengthened our five multidisciplinary research programs and opened new shared resources, most notably the Population Research Core that supports population-based cancer prevention and control research at UM/Sylvester. With assistance from the Population Research Core, we are increasing the diversity of clinical trial participants to represent the racial, ethnic, and socioeconomic composition of South Florida’s diverse and unique community. Much of this has been done under the thoughtful leadership of Joseph D. Rosenblatt, M.D., associate director, clinical and translational research, and the several senior scientists he’s already brought to South Florida. Dr. Rosenblatt joined the University of Miami School of Medicine in 2001 as division chief of Hematology-Oncology. His presence can be felt everywhere. UM/Sylvester’s Best Friend Many of you may have known or heard about Jay W. Weiss, whom we often describe as the “best friend UM/Sylvester will ever have.” As chairman of the board of governors, Jay led UM/Sylvester during its most challenging years, and did so with integrity, tenacity, and grace. Jay’s vision and leadership continually invigorated and inspired us to reach new heights. To Jay, who lost his battle with cancer earlier this year, and the many others who continue to support UM/Sylvester each and every day, we dedicate this report. As we continue our quest to cure cancer and to ensure the best possible quality of life for those suffering from this disease, we know we do so with the support of many friends and colleagues. During the past two years, UM/Sylvester has been the proud recipient of nearly $56 million in cancer-related research grants and more than $17 million in philanthropy (to support research). We continually are expanding our research and clinical facilities and planning for the day when we can start building much-needed new infrastructure. Cancer Incidence and Death Rates Despite all the success we’ve had as a nation and the important research that’s underway across the globe, cancer remains a threat to this society. According to the American Cancer Society, 1.3 million new cancer cases will be reported this year, and Florida stands second only to California, projecting more than 96,000 new cancer cases in 2004. But we have made progress, which I highlight below. According to the Annual Report to the Nation, 1 Americans’ risk of getting and dying from cancer continues to decline and survival rates for many cancers continue to improve: • Both overall observed cancer incidence rates and death rates from all cancers combined have dropped. • We’ve seen the first ever drops in lung cancer incidence rates in women. • The percentage of patients who have survived more than five years post-diagnosis has increased in the past two decades. UM/Sylvester Comprehensive Cancer Center Scientific Report 2004 i
I N T R O D U C T I O N A N D P R O G R E S S R E P O R T • Among men, cancer incidence rates have recently declined for seven of the top 15 cancer sites: lung, colon, oral cavity, leukemia, stomach, pancreas, and larynx. • In addition to lung cancer, incidence rates among women also have declined in: colon, cervix, pancreas, ovary, and oral cavity cancers. • Childhood cancers have shown some of the largest improvements in cancer survival during the past 20 years. • There are, however, wide variations in survival associated with race and ethnicity; in every racial and ethnic population, with the exception of Asian/Pacific Islander women, the risk of cancer death from all cancer sites combined was higher than the risk of death for non-Hispanic white patients. The State of Florida, the citizens of South Florida, and the University of Miami are investing heavily in translational research—with ideas flowing from the laboratory bench to the patient’s bedside and back again—which is the essence of a comprehensive cancer center, the essence of UM/Sylvester. I am proud to tell you about the important translational research underway at UM/Sylvester and the equally important basic science and cancer prevention and control research that undergirds and strengthens our efforts. PROGRESS REPORT Scientists at UM/Sylvester are grouped into five multidisciplinary research programs that reflect our strengths and our priorities—Cancer Prevention and Control, Clinical Oncology Research, Tumor Cell Biology, Tumor Immunology, and Viral Oncology. Our scientists work within the established research programs and with physicians in UM/Sylvester’s 15 multidisciplinary, sitebased oncology groups. Together we design and conduct the clinical trials necessary to test the value of new prevention, screening, diagnosis, and treatment protocols. Examples of significant research currently taking place at UM/Sylvester are included in this report, which is organized by multidisciplinary research program. We also have provided descriptions of each of our shared resources and a list of publications by author. Several research projects of particular note are highlighted here: Research Highlights Note: More information also can be found at www.sylvester.org. • UM/Sylvester is expanding the use of a vaccine for patients with non-small cell lung cancer. It now will be administered to two new groups of patients: those who have surgery to remove lung tumors and those who complete their first cycle of standard chemotherapy. The lung cancer vaccine was developed by Eckhard R. Podack, M.D., Ph.D., UM/Sylvester’s Associate Director, Basic Science and Chairman of Microbiology and Immunology, and has been available in research protocols at UM/Sylvester for more than three years. UM/Sylvester is the only facility in the United States that does immunotherapy using the B7.1 vaccine for lung cancer. Luis Raez, M.D., F.A.C.P., asssitant professor of Medicine and Epidemiology and Public Health, administered the vaccine to 19 people who had an expected survival of less than six months; six or them are still diseasefree and three have surpassed the three-year ii UM/Sylvester Comprehensive Cancer Center Scientific Report 2004
Page 1 and 2: S C I E N T I F I C R E P O R T 2 0
Page 3: I N T R O D U C T I O N A N D P R O
Page 7 and 8: I N T R O D U C T I O N A N D P R O
Page 9 and 10: I N T R O D U C T I O N A N D P R O
Page 11 and 12: L E A D E R S H I P MULTIDISCIPLINA
Page 13 and 14: L E A D E R S H I P EXTERNAL ADVISO
Page 15 and 16: C A N C E R P R E V E N T I O N A N
Page 47 and 48: C L I N I C A L O N C O L O G Y R E
Page 55 and 56:
C L I N I C A L O N C O L O G Y R E
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
T U M O R C E L L B I O L O G Y P R
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
T U M O R I M M U N O L O G Y P R O
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
V I R A L O N C O L O G Y P R O G R
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
S H A R E D R E S O U R C E S 3) La
Page 159 and 160:
S H A R E D R E S O U R C E S C E L
Page 161 and 162:
S H A R E D R E S O U R C E S D N A
Page 163 and 164:
S H A R E D R E S O U R C E S G E N
Page 165 and 166:
S H A R E D R E S O U R C E S I N F
Page 167 and 168:
S H A R E D R E S O U R C E S P O P
Page 169 and 170:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 171 and 172:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 173 and 174:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 175 and 176:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 177 and 178:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 179 and 180:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 181 and 182:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 183 and 184:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 185 and 186:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 187 and 188:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 189 and 190:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 191 and 192:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 193 and 194:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 195 and 196:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 197 and 198:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 199 and 200:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 201 and 202:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 203 and 204:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 205 and 206:
G L O S S A R Y IFN—interferon IL
show all

SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

Create successful ePaper yourself

Delete template?

Save as template?